BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
111.93
-0.83 (-0.74%)
At close: Jan 17, 2025, 4:00 PM
113.00
+1.07 (0.96%)
After-hours: Jan 17, 2025, 7:05 PM EST
BioNTech SE Revenue
BioNTech SE had revenue of 1.24B EUR in the quarter ending September 30, 2024, with 39.04% growth. This brings the company's revenue in the last twelve months to 3.04B, down -54.07% year-over-year. In the year 2023, BioNTech SE had annual revenue of 3.82B, down -77.94%.
Revenue (ttm)
3.04B EUR
Revenue Growth
-54.07%
P/S Ratio
7.95
Revenue / Employee
495,695 EUR
Employees
6,133
Market Cap
26.83B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
BNTX News
- 6 days ago - BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 10 days ago - BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst - Benzinga
- 24 days ago - BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties - Reuters
- 5 weeks ago - US FDA lifts partial clinical hold on BioNTech cancer drug study - Reuters
- 6 weeks ago - Why Is BioNTech Stock Trading Higher On Friday? - Benzinga
- 2 months ago - BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It. - Barrons
- 2 months ago - Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head - Investopedia